Stages of dementia symptoms and conditions

I am a 34 yr old woman who has suffered from migraines for 13 yrs and chronic head pain for most of my life. I have had sinus surgery, my vision checked, TMJ corrected and anything else I could think of to alleviate my headaches. I took various anti-depressants to treat for chronic pain. About 3 yrs ago I began taking Topamax after my grandmother & both my sisters went on it for migraines. We all have experienced success in treating the headaches and both sisters lost weight. Grandmother and I did not. We all still have migraines occasionally and my youngest sister cannot miss a dose w/out having a headache. My grandmother has had to discontinue Topamax because it was effecting her memory, speech, and concentration so badly. All of us experienced the "loss of words" problems at first, but learned to adapt and became used to it. But grandma is in her 70s and its not as easy for her. However, in the past month, I have been experiencing the same thing--memory loss, calling a place or object the wrong name, and poor concentration. I feel like I can't even read today. I was taking 150mg and thought I was pregnant so I started decreasing my dose down to 100mg to wean off. I'm not pregnant and I'm thinking of discontinuing the Topamax anyway. It's bad enough when I can't remember things at home, I can't work like this. I have always raved about how great Topamax is and that if it kept my head from hurting, I would take it forever. Now I feel like I'm in the early stages of dementia.

Cholesterol Decline May Be Associated With Early Stages of Dementia

By Will Boggs, MD

NEW YORK (Reuters Health) Jan 19 - A decline in total cholesterol
levels precedes the diagnosis of dementia by at least 15 years,
according to an epidemiologic study reported in the January issue of
the Archives of Neurology.

"Studies like this are extremely valuable because they can provide a
'window' on to processes going on early in dementia, allowing
researchers to look back in time at people's health and other
characteristics and compare these between people who develop dementia
and those who do not," Dr. Robert Stewart from King's College London,
UK told Reuters Health.

Dr. Stewart and colleagues used data from the Honolulu-Asia Aging
Study to compare the natural history of cholesterol level change over
a 26-year period between 56 men who were found to have dementia at
examination 3 years after the last cholesterol measurement and 971 men
who did not have dementia.

Total cholesterol levels at the beginning of the study did not differ
by later dementia status, the authors report, but the decline in
subsequent cholesterol levels was significantly steeper among men who
went on to develop dementia.

Adjustment for potential confounding factors strengthened the
association between cholesterol level decline and the development of
dementia, the results indicate.

The cholesterol level decline was most marked in men with dementia and
the APOE epsilon-4 allele and in those with dementia and worse self-
reported general health at the final cholesterol measurement, the
researchers note.

"The observed associations may not represent direct causal pathways,"
the investigators say. "Hypocholesterolemia is recognized to be
associated with frailty and poor general health. It also has been
found to be specifically associated with inflammatory markers and poor
nutritional status."

Rather, they suggest, "It is possible that the decline in cholesterol
levels is a marker for early processes that reflect neurodegenerative
changes and also lead to a decline in general health status."

The drop in cholesterol was not a result of medication. "Very few of
the participants in this study were receiving cholesterol lowering
treatment at the time the decline in cholesterol levels was observed
(there were few cholesterol lowering medications around at that time
in the 1970s), so medication was not responsible for this," Dr.
Stewart explained.

"The drop in cholesterol was instead probably caused by some other
event and was a 'marker' of risk rather than actually increasing the
risk itself," he concluded.

Arch Neurol 2007;64:103-107.